<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of the treatment of achalasia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of the treatment of achalasia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of the treatment of achalasia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stuart J Spechler, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nicholas J Talley, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kristen M Robson, MD, MBA, FACG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 05, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Achalasia is thought to result from progressive degeneration of ganglion cells in the myenteric plexus in the esophageal wall leading to failure of relaxation of the lower esophageal sphincter (LES) accompanied by a loss of peristalsis in the distal esophagus.
        </p>
        <p>
         This topic will review the management of achalasia. Our recommendations are based on society guidelines and data suggesting that achalasia treatment is best rendered in a phenotype-specific manner [
         <a href="#rid1">
          1-4
         </a>
         ]. The pathophysiology, etiology, clinical manifestations, and diagnosis of achalasia, as well as a more detailed discussion of pneumatic dilation, botulinum toxin injection, and surgical management of achalasia, are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/2268.html" rel="external">
          "Achalasia: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2245.html" rel="external">
          "Pneumatic dilation and botulinum toxin injection for achalasia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15060.html" rel="external">
          "Surgical myotomy for achalasia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/103958.html" rel="external">
          "Peroral endoscopic myotomy (POEM)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3680778">
         <span class="h1">
          TREATMENT APPROACH
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of achalasia is aimed primarily at decreasing the resting pressure in the lower esophageal sphincter (LES) to a level at which the sphincter no longer impedes the passage of ingested material (
         <a class="graphic graphic_diagnosticimage graphicRef70627" href="/z/d/graphic/70627.html" rel="external">
          image 1
         </a>
         ) [
         <a href="#rid5">
          5,6
         </a>
         ]. This can be accomplished by mechanical disruption of the muscle fibers of the LES (eg, pneumatic dilation, surgical myotomy, or peroral endoscopic myotomy [POEM]) or by pharmacologic reduction in LES pressure (eg, injection of botulinum toxin or use of oral nitrates). For any of the invasive therapies, results are best for patients with type II achalasia. Unfortunately, no treatment can reverse the degeneration of ganglion cells, restore the lost esophageal neurons, and hence, normalize esophageal function. Consequently, available treatments do not normalize swallowing; they merely improve it. Moreover, the efficacy of all these treatments tends to decrease with time. Consequently, patients will require long-term follow-up and will frequently need repeated or alternative treatments [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3681795">
         <span class="h2">
          Choice of treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who have average surgical risk, preferred options for treatment include pneumatic dilation, laparoscopic Heller myotomy with a partial fundoplication, and POEM (
         <a class="graphic graphic_algorithm graphicRef139061" href="/z/d/graphic/139061.html" rel="external">
          algorithm 1
         </a>
         ). Preoperative evaluation and risk assessment are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6616.html" rel="external">
          "Evaluation of cardiac risk prior to noncardiac surgery"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6917.html" rel="external">
          "Evaluation of perioperative pulmonary risk"
         </a>
         .)
        </p>
        <p>
         POEM has been proposed as the procedure of choice for type III achalasia because POEM can deliver a longer myotomy that is generally not possible with pneumatic dilation or the Heller procedure, and a longer myotomy might be more effective at controlling symptoms caused by the esophageal spasm of type III achalasia [
         <a href="#rid2">
          2,8
         </a>
         ]. Short-term results of POEM for types I and II achalasia are at least as effective (and perhaps even better) compared with pneumatic dilation and surgical myotomy, while data on long-term outcomes of POEM are accumulating [
         <a href="#rid8">
          8-10
         </a>
         ]. The efficacy of POEM for achalasia is presented in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/103958.html" rel="external">
          "Peroral endoscopic myotomy (POEM)", section on 'Outcomes of POEM for achalasia'
         </a>
         .)
        </p>
        <p>
         Pneumatic dilation, laparoscopic Heller myotomy, and POEM all are considered comparable effective therapies for patients with type I or type II achalasia. All of these invasive procedures ideally should be performed in high-volume centers of excellence, and the choice of initial therapy should be guided by the results of high-resolution manometry, patients' age and sex, patients' preference, and local institutional expertise. Patients with the best outcomes after pneumatic dilation are those older than 40 years, female patients, those with narrow esophageal diameter, and those with a type II pattern by high-resolution manometry [
         <a href="#rid11">
          11-16
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/2245.html" rel="external">
          "Pneumatic dilation and botulinum toxin injection for achalasia", section on 'Predictors of outcome'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2268.html" rel="external">
          "Achalasia: Pathogenesis, clinical manifestations, and diagnosis", section on 'High-resolution manometry'
         </a>
         ). For patients treated initially with myotomy (POEM or laparoscopic Heller myotomy) that fails to control symptoms, reasonable treatment options include pneumatic dilation or redo myotomy using either the same or an alternative myotomy technique (POEM or laparoscopic Heller myotomy) [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         For patients who elect to undergo pneumatic dilation, surgical myotomy or POEM can be performed subsequently if symptoms persist despite several attempts at pneumatic dilation. (See
         <a class="local">
          'Pneumatic dilation'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/2245.html" rel="external">
          "Pneumatic dilation and botulinum toxin injection for achalasia", section on 'Predictors of outcome'
         </a>
         and
         <a class="local">
          'Surgical myotomy'
         </a>
         below.)
        </p>
        <p>
         For patients who are not candidates for surgery, pneumatic dilation or POEM, or who are unwilling to undergo these procedures, we suggest a trial of botulinum toxin injection as this may improve swallowing. (See
         <a class="local">
          'Botulinum toxin injection'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/2245.html" rel="external">
          "Pneumatic dilation and botulinum toxin injection for achalasia", section on 'Botulinum toxin injection'
         </a>
         .)
        </p>
        <p>
         For patients who are unwilling or unable to tolerate surgery, pneumatic dilation, or POEM, and have failed botulinum toxin injections, we suggest pharmacologic therapy with nitrates. (See
         <a class="local">
          'Pharmacologic therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2407336140">
         <span class="h2">
          Options
         </span>
        </p>
        <p class="headingAnchor" id="H3682960">
         <span class="h3">
          Pneumatic dilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Forceful dilation with pneumatic balloon dilation of the LES weakens the LES by circumferential stretching or tearing of its muscle fibers [
         <a href="#rid17">
          17
         </a>
         ]. Pneumatic dilation should be performed by an experienced endoscopist. Multiple endoscopies are frequently required for graded pneumatic dilation. Patients undergoing pneumatic dilation must be good surgical candidates because perforations related to pneumatic dilation may require surgical repair. The technique, efficacy, and complications of pneumatic dilation are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2245.html" rel="external">
          "Pneumatic dilation and botulinum toxin injection for achalasia", section on 'Pneumatic dilation'
         </a>
         .)
        </p>
        <p>
         Pneumatic dilation appears to be the most cost-effective treatment for type II achalasia and has the advantage of being less invasive as compared with surgical myotomy or POEM [
         <a href="#rid18">
          18
         </a>
         ]. Initial success rates are high (85 percent at one month) and sustained in the short term (12 to 24 months), but efficacy wanes over time [
         <a href="#rid11">
          11
         </a>
         ]. Over four to six years, nearly one-third of patients have symptom relapse and require retreatment [
         <a href="#rid12">
          12,19-21
         </a>
         ]. Post-procedure complications include symptomatic esophageal perforation (approximately 2 percent) and heartburn (15 to 35 percent) [
         <a href="#rid11">
          11,22
         </a>
         ]. Subsequent pneumatic dilations are progressively less likely to result in a sustained remission [
         <a href="#rid22">
          22,23
         </a>
         ]. Other forms of therapy should, therefore, be considered for patients who have recurrent or persistent dysphagia after several pneumatic dilations. Patients who have undergone pneumatic dilation also may be at an increased risk of intraoperative complications if they subsequently require surgical myotomy, although this remains controversial [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2245.html" rel="external">
          "Pneumatic dilation and botulinum toxin injection for achalasia", section on 'Efficacy of PD'
         </a>
         .)
        </p>
        <p>
         Esophageal dilation with a tapered dilator (bougienage) or through-the-scope balloons is highly effective in the treatment of peptic esophageal strictures, but usually provides only temporary and incomplete relief, if any, for patients with achalasia [
         <a href="#rid25">
          25
         </a>
         ]. Definitive dilation therapy requires more forceful stretching of the LES than can be achieved with bougienage or through-the-scope balloons.
        </p>
        <p class="headingAnchor" id="H1988524">
         <span class="h3">
          Surgical myotomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgical myotomy, in which the LES is weakened by cutting its muscle fibers, has been the primary alternative to pneumatic dilation for achalasia. Heller myotomy is usually performed laparoscopically [
         <a href="#rid22">
          22,23,26-30
         </a>
         ]. Since LES disruption can cause reflux esophagitis, it is frequently combined with an antireflux procedure such as a partial fundoplication (Dor or Toupet fundoplication). Operative management of achalasia is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/15060.html" rel="external">
          "Surgical myotomy for achalasia", section on 'Fundoplication'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15060.html" rel="external">
          "Surgical myotomy for achalasia", section on 'Addition of a fundoplication'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overall efficacy and safety –
         </strong>
         Initial symptom relief is achieved in 90 percent of patients after surgical myotomy, which is similar to the rate reported in studies looking at medium-term outcomes (12 to more than 36 months) [
         <a href="#rid22">
          22
         </a>
         ]. As with endoscopic procedures, symptom relief wanes with time and patients often require retreatment. In one study that included 62 patients who had undergone surgical myotomy and partial fundoplication at a mean follow-up of 19 months, 38 percent of patients reported some dysphagia [
         <a href="#rid31">
          31
         </a>
         ]. Another large retrospective study included 1461 patients with achalasia, of which 81 percent had pneumatic dilatation and 19 percent had surgical myotomy as their first procedure [
         <a href="#rid32">
          32
         </a>
         ]. The cumulative risk of any subsequent treatment (dilatation, myotomy, or esophagectomy) after 1, 5, and 10 years was 37, 56, and 63 percent after initial pneumatic dilatation and 16, 30, and 37 percent after initial treatment with myotomy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The major disadvantages of surgery are the protracted recovery period and associated complications. Complications of laparoscopic myotomy include gastroesophageal reflux disease (GERD), perforation, pneumothorax, bleeding, vagal injury, and infection [
         <a href="#rid33">
          33
         </a>
         ]. However, the risk of GERD is significantly lower if an antireflux procedure is performed (9 versus 32 percent) [
         <a href="#rid22">
          22
         </a>
         ]. Pneumatic dilation has been performed in patients who fail to improve following surgical myotomy [
         <a href="#rid34">
          34,35
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15060.html" rel="external">
          "Surgical myotomy for achalasia", section on 'Postoperative complications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2245.html" rel="external">
          "Pneumatic dilation and botulinum toxin injection for achalasia", section on 'Patients who failed myotomy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surgical myotomy versus pneumatic dilation
         </strong>
         <strong>
          –
         </strong>
         Laparoscopic Heller myotomy is superior to a single pneumatic dilation in terms of efficacy and durability. However, the superiority of surgical myotomy over pneumatic dilation is less evident when compared with graded pneumatic dilation, which involves repeated dilations as mandated by the clinical response.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a retrospective study of 179 patients that compared pneumatic dilation with Heller myotomy, the success of Heller myotomy was comparable with pneumatic dilation after six years of follow-up (57 versus 44 percent) [
         <a href="#rid12">
          12
         </a>
         ]. Success was defined as dysphagia or regurgitation less than three times per week or freedom from alternative treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A meta-analysis that compared graded pneumatic dilation with laparoscopic surgical myotomy included three randomized trials with 346 patients published between 2007 and 2011 [
         <a href="#rid36">
          36
         </a>
         ]. After up to one year of follow-up, surgical myotomy was more effective than pneumatic dilation (86 versus 77 percent) and was associated with fewer adverse events (0.6 versus 5 percent). However, there were no differences in post-procedure LES pressure, rate of gastroesophageal reflux, and quality of life.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The largest trial in the meta-analysis included 201 patients who were assigned to either pneumatic dilation or laparoscopic Heller myotomy [
         <a href="#rid11">
          11
         </a>
         ]. Patients were followed for a mean of 43 months. In an intention-to-treat analysis, there was no significant difference between the groups with regard to therapeutic success. At one-year follow-up, the success rate for pneumatic dilation was 90 percent, and for laparoscopic myotomy it was 93 percent. After two years, the success rates were 86 and 90 percent, respectively. In addition, after two years of follow-up there was no significant difference between the groups with regard to LES pressure, esophageal emptying, quality of life, or esophageal acid exposure. Subgroup analyses found that patients younger than 40 years were at increased risk of requiring redilation after pneumatic dilation. However, a number of factors should be considered when interpreting the results of this trial [
         <a href="#rid37">
          37
         </a>
         ]. First, the protocol for pneumatic dilation used in this trial was rigorous, involving up to three sets of balloon dilations over a period of &gt;2 years, with individual sets including as many as three separate dilation sessions. Each dilation session generally means a day lost from work. By contrast, the inconvenience of Heller myotomy is primarily "up front," involving the operation itself and the postoperative recovery. Furthermore, esophageal perforations occurred in approximately 4 percent of patients treated with this rigorous pneumatic dilation protocol, requiring hospitalization and, in some cases, emergency surgical repair with an open (rather than laparoscopic) procedure. In addition, the balloon dilations and operations in this trial were performed by very experienced gastroenterologists and surgeons. It is not clear that their excellent results can be reproduced in community practices. After five years of follow-up, there was no significant difference in success rates between the two groups [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Surgery may be less cost-effective than initial pneumatic dilation [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1899395572">
         <span class="h3">
          Peroral endoscopic myotomy (POEM)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Peroral endoscopic myotomy (POEM), a form of natural orifice transluminal endoscopic surgery (NOTES), is an endoscopic method for performing myotomy of the LES [
         <a href="#rid39">
          39-46
         </a>
         ]. During POEM, the endoscopist makes an incision in the esophageal mucosa, and the endoscope is passed through that incision into the esophageal submucosa, creating a submucosal tunnel that is extended distally into the gastric cardia. A diathermic scalpel then is passed through the endoscope to sever the muscle of the muscularis propria in and around the LES. In addition, the myotomy can extend well above the LES, which may be an advantage in treating type III achalasia in which spasm in the esophageal body contributes to symptoms. Unlike surgical myotomy, which often is combined with fundoplication to prevent reflux, POEM includes no antireflux procedure. Consequently, POEM can result in severe GERD. Indeed, it has been suggested that patients undergoing POEM should be counseled regarding the increased risk of postprocedure reflux compared with other treatments (pneumatic dilation, laparoscopic Heller myotomy) [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         The use of POEM is supported by clinical trials and observational data from highly specialized centers [
         <a href="#rid9">
          9,10,47,48
         </a>
         ]. POEM became available after other therapeutic interventions, and long-term data on outcomes are also awaited (see
         <a class="medical medical_review" href="/z/d/html/103958.html" rel="external">
          "Peroral endoscopic myotomy (POEM)", section on 'Outcomes of POEM for achalasia'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          POEM versus pneumatic dilation
         </strong>
         <strong>
          –
         </strong>
         In an unblinded, randomized trial that was conducted at six centers with expertise in achalasia management and included 133 adults with newly diagnosed achalasia, POEM resulted in higher rates of treatment success (defined as an Eckardt score ≤3 and absence of severe complications at two years) compared with pneumatic dilation with a 30 or 35 mm balloon (92 versus 53 percent) [
         <a href="#rid10">
          10
         </a>
         ]. No serious adverse events were reported in the POEM group, whereas two serious adverse events occurred with pneumatic dilation (one patient with perforation and one patient with chest pain resulting in hospitalization). However, rates of reflux esophagitis were higher in the POEM group (41 versus 7 percent). The study was limited by the following: unblinded design, use of a 30 or 35 mm balloon (rather than a 40 mm balloon that is often used in clinical practice), and lack of significant differences in physiologic markers of treatment success between groups [
         <a href="#rid49">
          49
         </a>
         ]. Nevertheless, it does appear that POEM performs better than pneumatic dilation for symptom improvement but with a greater risk for erosive esophagitis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          POEM versus laparoscopic Heller myotomy –
         </strong>
         Relief of dysphagia is similar for patients with POEM and laparoscopic Heller myotomy with fundoplication, whereas the risk of erosive esophagitis is greater after POEM. In a randomized trial including 221 adults with achalasia, rates of clinical success (defined as an Eckardt score ≤3 without use of additional treatments at two years) were not significantly different for patients who underwent POEM compared with laparoscopic Heller myotomy with Dor fundoplication (83 versus 82 percent) [
         <a href="#rid9">
          9
         </a>
         ]. Compared with laparoscopic Heller myotomy, POEM was associated with a lower rate of severe adverse events (2.7 versus 7.3 percent) but with a higher rate of reflux esophagitis (44 versus 29 percent) at two years. Limitations of the trial included lack of blinding and low participation rate among eligible patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other studies
         </strong>
         <strong>
          –
         </strong>
         An earlier meta-analysis of mostly observational studies concluded that POEM was more likely to be successful than laparoscopic Heller myotomy for both type I and type III achalasia, and that pneumatic dilation had a lower, but still acceptable, treatment success rate than either POEM or laparoscopic Heller myotomy [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Favorable outcomes for POEM have been reported in patients with achalasia conditions that often do not respond well to conventional therapies, such as "end stage" achalasia (markedly dilated, sigmoid esophagus), and in patients who have failed prior endoscopic and surgical achalasia treatments [
         <a href="#rid2">
          2,51,52
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3682212">
         <span class="h3">
          Botulinum toxin injection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Botulinum toxin therapy can be considered in patients who are not good candidates for more definitive therapy with pneumatic dilation, surgical myotomy, or POEM, and this approach is consistent with guidelines from the American Society for Gastrointestinal Endoscopy (ASGE) [
         <a href="#rid8">
          8
         </a>
         ]. Botulinum toxin injected into the LES poisons the excitatory (acetylcholine-releasing) neurons that increase LES smooth muscle tone. The net effect is a decrease in basal LES pressure in patients with achalasia, which allows emptying of the esophagus when esophageal pressures exceed that of the partially paralyzed LES.
        </p>
        <p>
         Botulinum toxin injection has the advantage of being less invasive as compared with surgery and can be easily performed during routine endoscopy. Initial success rates with botulinum toxin are comparable to pneumatic dilation and surgical myotomy [
         <a href="#rid22">
          22
         </a>
         ]. However, patients treated with botulinum toxin have more frequent relapses and a shorter time to relapse [
         <a href="#rid53">
          53
         </a>
         ]. Greater than 50 percent of patients with achalasia treated with botulinum toxin require retreatment within 6 to 12 months. Repeated botulinum toxin injections may also make a subsequent Heller myotomy more challenging [
         <a href="#rid54">
          54
         </a>
         ]. The technique of botulinum toxin injection to treat achalasia, efficacy, and complications are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2245.html" rel="external">
          "Pneumatic dilation and botulinum toxin injection for achalasia", section on 'Comparative studies'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2245.html" rel="external">
          "Pneumatic dilation and botulinum toxin injection for achalasia", section on 'Botulinum toxin injection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3682306">
         <span class="h3">
          Pharmacologic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Medical therapy is the least effective treatment option in patients with achalasia, but should be considered in patients who are unwilling or unable to tolerate invasive therapy for achalasia and for patients who have failed botulinum toxin injections.
        </p>
        <p>
         Because nitrates are short-acting, sublingual
         <a class="drug drug_general" data-topicid="8580" href="/z/d/drug information/8580.html" rel="external">
          isosorbide dinitrate
         </a>
         (5 mg) (where available) is administered 10 to 15 minutes before meals. Sublingual
         <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">
          nitroglycerin
         </a>
         0.4 mg is an alternative if sublingual isosorbide dinitrate is unavailable and nitrate therapy is indicated [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
         Nitrates relax the smooth muscle of the LES both in normal individuals and in patients with achalasia. Treatment with sublingual
         <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">
          nitroglycerin
         </a>
         may result in short-term symptomatic improvement; however, the benefit is not durable [
         <a href="#rid56">
          56
         </a>
         ]. In addition, side effects such as headache and flushing are common, and contraindications to nitrate use are discussed separately [
         <a href="#rid57">
          57,58
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1549.html" rel="external">
          "Nitrates in the management of chronic coronary syndrome", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
         Although 5-phosphodiesterase inhibitors (eg,
         <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">
          sildenafil
         </a>
         ), anticholinergics (eg,
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9350" href="/z/d/drug information/9350.html" rel="external">
          dicyclomine
         </a>
         , cimetropium bromide), beta adrenergic agonists (eg,
         <a class="drug drug_general" data-topicid="9977" href="/z/d/drug information/9977.html" rel="external">
          terbutaline
         </a>
         ), and
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         have been used to treat achalasia, there are very limited data to support their use.
        </p>
        <p>
         While studies have described variable efficacy rates for treatment with calcium channel blockers for achalasia [
         <a href="#rid57">
          57,59
         </a>
         ], we avoid the use of short-acting
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         because of the risk of adverse effects including severe hypotension and ischemic complications that are discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3830.html" rel="external">
          "Management of severe asymptomatic hypertension (hypertensive urgencies) in adults", section on 'When the pressure should be lowered over a period of hours'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4205730336">
         <span class="h1">
          SURVEILLANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk of esophageal cancer is increased in patients with achalasia, but the absolute risk is low. We therefore do not perform endoscopic surveillance in patients with achalasia. Our recommendations are consistent with the American Society for Gastrointestinal Endoscopy (ASGE) and the American College of Gastroenterology (ACG) [
         <a href="#rid3">
          3,60
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2268.html" rel="external">
          "Achalasia: Pathogenesis, clinical manifestations, and diagnosis", section on 'Cancer risk'
         </a>
         .)
        </p>
        <p>
         Although some experts have suggested endoscopic or radiographic surveillance in patients with achalasia to predict or detect disease progression, studies are needed to determine whether surveillance improves outcomes [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2923594000">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/118140.html" rel="external">
          "Society guideline links: Achalasia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H607624320">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/16153.html" rel="external">
          "Patient education: Achalasia (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/1998.html" rel="external">
          "Patient education: Achalasia (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Background –
         </strong>
         Achalasia is thought to result from progressive degeneration of ganglion cells in the myenteric plexus in the esophageal wall. The symptoms and signs of achalasia are due primarily to failure of relaxation of the lower esophageal sphincter (LES), although spasm in the body of the esophagus can also contribute to symptoms, especially in type III achalasia. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Approach to treatment –
         </strong>
         Treatment options include mechanical disruption of the muscle fibers of the LES (eg, pneumatic dilation, laparoscopic Heller myotomy, or peroral endoscopic myotomy [POEM]) or biochemical reduction in LES pressure (eg, injection of botulinum toxin, use of oral nitrates) (
         <a class="graphic graphic_algorithm graphicRef139061" href="/z/d/graphic/139061.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Treatment approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Pneumatic balloon dilation, POEM, and surgical myotomy have comparable success rates for the treatment of type I and type II achalasia. POEM appears to be preferable for type III achalasia. However, the efficacy of all achalasia treatments decrease over time, and many patients will require repeat treatment within 10 years.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although botulinum toxin has high initial success rates that are comparable to pneumatic dilation and surgery, patients treated with botulinum toxin have more frequent relapses and a shorter time to relapse. Botulinum toxin injection is reserved for patients who cannot undergo more durable therapy. Medical therapy with nitrates is often ineffective and is limited by side effects. (See
         <a class="local">
          'Pneumatic dilation'
         </a>
         above and
         <a class="local">
          'Surgical myotomy'
         </a>
         above and
         <a class="local">
          'Botulinum toxin injection'
         </a>
         above and
         <a class="local">
          'Pharmacologic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients who are surgical candidates
         </strong>
         <strong>
          –
         </strong>
         For patients with achalasia who are good surgical candidates, we suggest treatment with pneumatic dilation, surgical myotomy, or POEM rather than botulinum toxin injection (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Choice of treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Since pneumatic dilation, laparoscopic Heller myotomy, and POEM are comparable effective therapies for type I or type II achalasia, the choice among these procedures should be based on local expertise. In settings where there is equal expertise in these procedures, we have a detailed discussion with the patient on the risks and benefits of the procedures and encourage shared decision-making. Surgical myotomy may be preferable in patients younger than 40 years of age due to an increased need for redilation in this age group. However, other experts, including other authors for UpToDate, disagree and would perform surgical myotomy as initial therapy for the majority of healthy patients. If local expertise in both procedures is lacking, we would refer patients to an esophageal center of excellence. (See
         <a class="medical medical_review" href="/z/d/html/2245.html" rel="external">
          "Pneumatic dilation and botulinum toxin injection for achalasia", section on 'Predictors of outcome'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15060.html" rel="external">
          "Surgical myotomy for achalasia", section on 'Surgical myotomy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         POEM is an effective submucosal endoscopic technique for performing myotomy of the LES and more proximal esophageal muscle. In addition, good results for POEM have been reported in patients with achalasia conditions that often do not respond well to conventional therapies, such as type III (spastic) achalasia and "end-stage" achalasia (markedly dilated, sigmoid esophagus), and in patients who have failed prior endoscopic and surgical achalasia treatments. The role of POEM in the treatment of achalasia continues to evolve, although there is a consensus that POEM is the procedure of choice for the treatment of type III achalasia. It has been suggested that patients undergoing POEM should be counseled regarding the increased risk of post-procedure reflux compared with other treatments. (See
         <a class="local">
          'Peroral endoscopic myotomy (POEM)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients who are not surgical candidates –
         </strong>
         For patients who are at high risk for complications of invasive procedures (such as older adults with comorbid illnesses), we suggest injection of botulinum toxin into the LES rather than pharmacologic therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Pharmacologic therapy (eg, nitrates) can be considered in patients who cannot tolerate upper endoscopy with sedation or who do not respond to treatment with botulinum toxin. (See
         <a class="local">
          'Botulinum toxin injection'
         </a>
         above and
         <a class="local">
          'Pharmacologic therapy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2245.html" rel="external">
          "Pneumatic dilation and botulinum toxin injection for achalasia"
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Zaninotto G, Bennett C, Boeckxstaens G, et al. The 2018 ISDE achalasia guidelines. Dis Esophagus 2018; 31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahrilas PJ, Bredenoord AJ, Carlson DA, Pandolfino JE. Advances in Management of Esophageal Motility Disorders. Clin Gastroenterol Hepatol 2018; 16:1692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaezi MF, Pandolfino JE, Yadlapati RH, et al. ACG Clinical Guidelines: Diagnosis and Management of Achalasia. Am J Gastroenterol 2020; 115:1393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahrilas PJ, Katzka D, Richter JE. Clinical Practice Update: The Use of Per-Oral Endoscopic Myotomy in Achalasia: Expert Review and Best Practice Advice From the AGA Institute. Gastroenterology 2017; 153:1205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spiess AE, Kahrilas PJ. Treating achalasia: from whalebone to laparoscope. JAMA 1998; 280:638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boeckxstaens GE, Zaninotto G, Richter JE. Achalasia. Lancet 2014; 383:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahrilas PJ. Treating achalasia; more than just flipping a coin. Gut 2016; 65:726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khashab MA, Vela MF, Thosani N, et al. ASGE guideline on the management of achalasia. Gastrointest Endosc 2020; 91:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Werner YB, Hakanson B, Martinek J, et al. Endoscopic or Surgical Myotomy in Patients with Idiopathic Achalasia. N Engl J Med 2019; 381:2219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ponds FA, Fockens P, Lei A, et al. Effect of Peroral Endoscopic Myotomy vs Pneumatic Dilation on Symptom Severity and Treatment Outcomes Among Treatment-Naive Patients With Achalasia: A Randomized Clinical Trial. JAMA 2019; 322:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boeckxstaens GE, Annese V, des Varannes SB, et al. Pneumatic dilation versus laparoscopic Heller's myotomy for idiopathic achalasia. N Engl J Med 2011; 364:1807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vela MF, Richter JE, Khandwala F, et al. The long-term efficacy of pneumatic dilatation and Heller myotomy for the treatment of achalasia. Clin Gastroenterol Hepatol 2006; 4:580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rohof WO, Salvador R, Annese V, et al. Outcomes of treatment for achalasia depend on manometric subtype. Gastroenterology 2013; 144:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vantrappen G, Hellemans J, Deloof W, et al. Treatment of achalasia with pneumatic dilatations. Gut 1971; 12:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaezi MF, Baker ME, Achkar E, Richter JE. Timed barium oesophagram: better predictor of long term success after pneumatic dilation in achalasia than symptom assessment. Gut 2002; 50:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pandolfino JE, Kwiatek MA, Nealis T, et al. Achalasia: a new clinically relevant classification by high-resolution manometry. Gastroenterology 2008; 135:1526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borhan-Manesh F, Kaviani MJ, Taghavi AR. The efficacy of balloon dilation in achalasia is the result of stretching of the lower esophageal sphincter, not muscular disruption. Dis Esophagus 2016; 29:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kostic S, Johnsson E, Kjellin A, et al. Health economic evaluation of therapeutic strategies in patients with idiopathic achalasia: results of a randomized trial comparing pneumatic dilatation with laparoscopic cardiomyotomy. Surg Endosc 2007; 21:1184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hulselmans M, Vanuytsel T, Degreef T, et al. Long-term outcome of pneumatic dilation in the treatment of achalasia. Clin Gastroenterol Hepatol 2010; 8:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zerbib F, Thétiot V, Richy F, et al. Repeated pneumatic dilations as long-term maintenance therapy for esophageal achalasia. Am J Gastroenterol 2006; 101:692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elliott TR, Wu PI, Fuentealba S, et al. Long-term outcome following pneumatic dilatation as initial therapy for idiopathic achalasia: an 18-year single-centre experience. Aliment Pharmacol Ther 2013; 37:1210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campos GM, Vittinghoff E, Rabl C, et al. Endoscopic and surgical treatments for achalasia: a systematic review and meta-analysis. Ann Surg 2009; 249:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           West RL, Hirsch DP, Bartelsman JF, et al. Long term results of pneumatic dilation in achalasia followed for more than 5 years. Am J Gastroenterol 2002; 97:1346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morino M, Rebecchi F, Festa V, Garrone C. Preoperative pneumatic dilatation represents a risk factor for laparoscopic Heller myotomy. Surg Endosc 1997; 11:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vantrappen G, Hellemans J. Treatment of achalasia and related motor disorders. Gastroenterology 1980; 79:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hunter JG, Trus TL, Branum GD, Waring JP. Laparoscopic Heller myotomy and fundoplication for achalasia. Ann Surg 1997; 225:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogt D, Curet M, Pitcher D, et al. Successful treatment of esophageal achalasia with laparoscopic Heller myotomy and Toupet fundoplication. Am J Surg 1997; 174:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ancona E, Anselmino M, Zaninotto G, et al. Esophageal achalasia: laparoscopic versus conventional open Heller-Dor operation. Am J Surg 1995; 170:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holzman MD, Sharp KW, Ladipo JK, et al. Laparoscopic surgical treatment of achalasia. Am J Surg 1997; 173:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arreola-Risa C, Sinanan M, Pellegrini CA. Thoracoscopic Heller's myotomy. Treatment of achalasia by the videoendoscopic approach. Chest Surg Clin N Am 1995; 5:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luketich JD, Fernando HC, Christie NA, et al. Outcomes after minimally invasive esophagomyotomy. Ann Thorac Surg 2001; 72:1909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopushinsky SR, Urbach DR. Pneumatic dilatation and surgical myotomy for achalasia. JAMA 2006; 296:2227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lynch KL, Pandolfino JE, Howden CW, Kahrilas PJ. Major complications of pneumatic dilation and Heller myotomy for achalasia: single-center experience and systematic review of the literature. Am J Gastroenterol 2012; 107:1817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gockel I, Timm S, Sgourakis GG, et al. Achalasia--if surgical treatment fails: analysis of remedial surgery. J Gastrointest Surg 2010; 14 Suppl 1:S46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumbhari V, Behary J, Szczesniak M, et al. Efficacy and safety of pneumatic dilatation for achalasia in the treatment of post-myotomy symptom relapse. Am J Gastroenterol 2013; 108:1076.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yaghoobi M, Mayrand S, Martel M, et al. Laparoscopic Heller's myotomy versus pneumatic dilation in the treatment of idiopathic achalasia: a meta-analysis of randomized, controlled trials. Gastrointest Endosc 2013; 78:468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spechler SJ. Pneumatic dilation and laparoscopic Heller's myotomy equally effective for achalasia. N Engl J Med 2011; 364:1868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moonen A, Annese V, Belmans A, et al. Long-term results of the European achalasia trial: a multicentre randomised controlled trial comparing pneumatic dilation versus laparoscopic Heller myotomy. Gut 2016; 65:732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasricha PJ, Hawari R, Ahmed I, et al. Submucosal endoscopic esophageal myotomy: a novel experimental approach for the treatment of achalasia. Endoscopy 2007; 39:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Renteln D, Inoue H, Minami H, et al. Peroral endoscopic myotomy for the treatment of achalasia: a prospective single center study. Am J Gastroenterol 2012; 107:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inoue H, Minami H, Kobayashi Y, et al. Peroral endoscopic myotomy (POEM) for esophageal achalasia. Endoscopy 2010; 42:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swanstrom LL, Kurian A, Dunst CM, et al. Long-term outcomes of an endoscopic myotomy for achalasia: the POEM procedure. Ann Surg 2012; 256:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verlaan T, Rohof WO, Bredenoord AJ, et al. Effect of peroral endoscopic myotomy on esophagogastric junction physiology in patients with achalasia. Gastrointest Endosc 2013; 78:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inoue H, Ikeda H, Onimaru M, et al. Clinical results in 300 cases of POEM for esophageal achalasia: A single institute registered prospective study (abstract). Gastrointest Endosc 2013; 77:AB121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Von Renteln D, Fuchs KH, Fockens P, et al. Endoscopic versus surgical myotomy for idiopathic achalasia: Results of a prospective multicenter study and comparison with laparoscopic surgery (abstract). Gastrointest Endosc 2013; 77:AB122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li QL, Chen WF, Zhou PH, et al. Peroral endoscopic myotomy for the treatment of achalasia: a clinical comparative study of endoscopic full-thickness and circular muscle myotomy. J Am Coll Surg 2013; 217:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inoue H, Sato H, Ikeda H, et al. Per-Oral Endoscopic Myotomy: A Series of 500 Patients. J Am Coll Surg 2015; 221:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hungness ES, Sternbach JM, Teitelbaum EN, et al. Per-oral Endoscopic Myotomy (POEM) After the Learning Curve: Durable Long-term Results With a Low Complication Rate. Ann Surg 2016; 264:508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yadlapati R, Gupta S. Peroral Endoscopic Myotomy versus Pneumatic Dilation in Achalasia: Dissecting the Randomized Controlled Trial. Gastroenterology 2020; 158:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andolfi C, Fisichella PM. Meta-analysis of clinical outcome after treatment for achalasia based on manometric subtypes. Br J Surg 2019; 106:332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumbhari V, Tieu AH, Onimaru M, et al. Peroral endoscopic myotomy (POEM) vs laparoscopic Heller myotomy (LHM) for the treatment of Type III achalasia in 75 patients: a multicenter comparative study. Endosc Int Open 2015; 3:E195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orenstein SB, Raigani S, Wu YV, et al. Peroral endoscopic myotomy (POEM) leads to similar results in patients with and without prior endoscopic or surgical therapy. Surg Endosc 2015; 29:1064.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang L, Li YM, Li L. Meta-analysis of randomized and controlled treatment trials for achalasia. Dig Dis Sci 2009; 54:2303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith CD, Stival A, Howell DL, Swafford V. Endoscopic therapy for achalasia before Heller myotomy results in worse outcomes than heller myotomy alone. Ann Surg 2006; 243:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wen ZH, Gardener E, Wang YP. Nitrates for achalasia. Cochrane Database Syst Rev 2004; :CD002299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahrilas PJ, Pandolfino JE. Treatments for achalasia in 2017: how to choose among them. Curr Opin Gastroenterol 2017; 33:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gelfond M, Rozen P, Gilat T. Isosorbide dinitrate and nifedipine treatment of achalasia: a clinical, manometric and radionuclide evaluation. Gastroenterology 1982; 83:963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bassotti G, Annese V. Review article: pharmacological options in achalasia. Aliment Pharmacol Ther 1999; 13:1391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coccia G, Bortolotti M, Michetti P, Dodero M. Prospective clinical and manometric study comparing pneumatic dilatation and sublingual nifedipine in the treatment of oesophageal achalasia. Gut 1991; 32:604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirota WK, Zuckerman MJ, Adler DG, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc 2006; 63:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eckardt AJ, Eckardt VF. Editorial: Cancer surveillance in achalasia: better late than never? Am J Gastroenterol 2010; 105:2150.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2261 Version 37.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30169645" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The 2018 ISDE achalasia guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29702296" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Advances in Management of Esophageal Motility Disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32773454" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : ACG Clinical Guidelines: Diagnosis and Management of Achalasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28989059" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Clinical Practice Update: The Use of Per-Oral Endoscopic Myotomy in Achalasia: Expert Review and Best Practice Advice From the AGA Institute.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9718057" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Treating achalasia: from whalebone to laparoscope.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23871090" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Achalasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26743013" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Treating achalasia; more than just flipping a coin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31839408" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : ASGE guideline on the management of achalasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31800987" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Endoscopic or Surgical Myotomy in Patients with Idiopathic Achalasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31287522" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Effect of Peroral Endoscopic Myotomy vs Pneumatic Dilation on Symptom Severity and Treatment Outcomes Among Treatment-Naive Patients With Achalasia: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21561346" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Pneumatic dilation versus laparoscopic Heller's myotomy for idiopathic achalasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16630776" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The long-term efficacy of pneumatic dilatation and Heller myotomy for the treatment of achalasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23277105" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Outcomes of treatment for achalasia depend on manometric subtype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5574797" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Treatment of achalasia with pneumatic dilatations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12010876" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Timed barium oesophagram: better predictor of long term success after pneumatic dilation in achalasia than symptom assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18722376" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Achalasia: a new clinically relevant classification by high-resolution manometry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25765473" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The efficacy of balloon dilation in achalasia is the result of stretching of the lower esophageal sphincter, not muscular disruption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17514399" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Health economic evaluation of therapeutic strategies in patients with idiopathic achalasia: results of a randomized trial comparing pneumatic dilatation with laparoscopic cardiomyotomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19782766" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Long-term outcome of pneumatic dilation in the treatment of achalasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16635216" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Repeated pneumatic dilations as long-term maintenance therapy for esophageal achalasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23659347" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Long-term outcome following pneumatic dilatation as initial therapy for idiopathic achalasia: an 18-year single-centre experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19106675" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Endoscopic and surgical treatments for achalasia: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12094848" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Long term results of pneumatic dilation in achalasia followed for more than 5 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9094277" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Preoperative pneumatic dilatation represents a risk factor for laparoscopic Heller myotomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6991359" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Treatment of achalasia and related motor disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9230806" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Laparoscopic Heller myotomy and fundoplication for achalasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9409602" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Successful treatment of esophageal achalasia with laparoscopic Heller myotomy and Toupet fundoplication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7661295" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Esophageal achalasia: laparoscopic versus conventional open Heller-Dor operation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9136786" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Laparoscopic surgical treatment of achalasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7583032" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Thoracoscopic Heller's myotomy. Treatment of achalasia by the videoendoscopic approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11789770" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Outcomes after minimally invasive esophagomyotomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17090769" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Pneumatic dilatation and surgical myotomy for achalasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23032978" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Major complications of pneumatic dilation and Heller myotomy for achalasia: single-center experience and systematic review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19856034" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Achalasia--if surgical treatment fails: analysis of remedial surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23458850" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Efficacy and safety of pneumatic dilatation for achalasia in the treatment of post-myotomy symptom relapse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23684149" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Laparoscopic Heller's myotomy versus pneumatic dilation in the treatment of idiopathic achalasia: a meta-analysis of randomized, controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21561354" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Pneumatic dilation and laparoscopic Heller's myotomy equally effective for achalasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26614104" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Long-term results of the European achalasia trial: a multicentre randomised controlled trial comparing pneumatic dilation versus laparoscopic Heller myotomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17703382" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Submucosal endoscopic esophageal myotomy: a novel experimental approach for the treatment of achalasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22068665" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Peroral endoscopic myotomy for the treatment of achalasia: a prospective single center study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20354937" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Peroral endoscopic myotomy (POEM) for esophageal achalasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22982946" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Long-term outcomes of an endoscopic myotomy for achalasia: the POEM procedure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23453184" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Effect of peroral endoscopic myotomy on esophagogastric junction physiology in patients with achalasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Clinical results in 300 cases of POEM for esophageal achalasia: A single institute registered prospective study (abstract)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Endoscopic versus surgical myotomy for idiopathic achalasia: Results of a prospective multicenter study and comparison with laparoscopic surgery (abstract)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23891074" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Peroral endoscopic myotomy for the treatment of achalasia: a clinical comparative study of endoscopic full-thickness and circular muscle myotomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26206634" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Per-Oral Endoscopic Myotomy: A Series of 500 Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27513156" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Per-oral Endoscopic Myotomy (POEM) After the Learning Curve: Durable Long-term Results With a Low Complication Rate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31704302" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Peroral Endoscopic Myotomy versus Pneumatic Dilation in Achalasia: Dissecting the Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30690706" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Meta-analysis of clinical outcome after treatment for achalasia based on manometric subtypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26171430" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Peroral endoscopic myotomy (POEM) vs laparoscopic Heller myotomy (LHM) for the treatment of Type III achalasia in 75 patients: a multicenter comparative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25249143" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Peroral endoscopic myotomy (POEM) leads to similar results in patients with and without prior endoscopic or surgical therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19107596" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Meta-analysis of randomized and controlled treatment trials for achalasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16632991" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Endoscopic therapy for achalasia before Heller myotomy results in worse outcomes than heller myotomy alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14973987" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Nitrates for achalasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28426463" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Treatments for achalasia in 2017: how to choose among them.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6288509" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Isosorbide dinitrate and nifedipine treatment of achalasia: a clinical, manometric and radionuclide evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10571593" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Review article: pharmacological options in achalasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2060867" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Prospective clinical and manometric study comparing pneumatic dilatation and sublingual nifedipine in the treatment of oesophageal achalasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16564854" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20927062" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Editorial: Cancer surveillance in achalasia: better late than never?
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
